Written answer
Medicinal Products
826. Deputy Cathal Crowe asked the Minister for Health if she will provide an update on the current status of the statutory pricing and reimbursement negotiations between the HSE and the manufacturer regarding a drug (details supplied); if she acknowledges the financial inequity faced by women with a history of hormone-positive breast cancer who are clinically precluded from taking conventional hormone replacement therapy and must pay out-of-pocket for non-hormonal alternatives; and if she will make a statement on the matter. [78736/26]
Comment on this
The State recognises the importance of providing the best care possible to patients with these conditions. Women’s Health has been and continues to be a focus of Government since taking office. We have made real progress in improving the healthcare available to women in Ireland.
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices.
The HSE has advised that it is committed to providing access to as many medicines as possible, in as timely a fashion as possible, from the resources available (provided) to it.
The HSE must robustly assess applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to Irish citizens and patients.
There are formal processes which govern applications for the pricing and reimbursement of medicines, and new uses of existing medicines, to be funded and / or reimbursed. HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds.
The Drugs Group is the national committee which the HSE has in place to make recommendations on the pricing and reimbursement of medicines. The membership of the HSE Drugs Group includes public interest members. Pharmacoeconomic reports are reviewed by the HSE Drugs Group along with the outputs of commercial negotiations, and any patient group submission(s) received. The HSE Drugs Group considers all of the evidence and makes a recommendation to the HSE Senior Management Team (HSE SMT).
The decision-making authority is the HSE SMT. The HSE SMT decides on the basis of all the demands it is faced with (across all services) - whether it can fund a new medicine, or new use of an existing medicine, from the resources that have been provided to it in line with the health (Pricing and Supply of Medical Goods) Act 2013.
In terms of the specific details of the application for pricing and reimbursement of Fezolinetant (Veoza™).
The HSE received an application for pricing / reimbursement for Fezolinetant (Veoza™) indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.
The first step in the process is the submission of a Rapid Review dossier (a clinical and economic dossier) to the National Centre for Pharmacoeconomics (NCPE) for assessment. The HSE commissioned the Rapid Review process on 9th February 2024.
The NCPE Rapid Review assessment report was completed on 12th March 2024. The NCPE advised the HSE that a full Health Technology Assessment (HTA) was recommended to assess the clinical effectiveness and cost effectiveness of Fezolinetant (Veoza™) compared with the current standard of care.
The HSE commissioned a full HTA on 8th April 2024 as per agreed processes.
The HTA was completed by the NCPE on 17th April 2026. The NCPE recommended that Fezolinetant (Veoza™) be considered for reimbursement if cost effectiveness could be improved relative to existing treatments. Fezolinetant (Veoza™). HTA ID: 24005 | National Centre for Pharmacoeconomics
The HSE Corporate Pharmaceutical Unit (CPU) is the interface between the HSE and the Pharmaceutical Industry in relation to medicine pricing and reimbursement applications.
The HSE CPU met with the applicant to discuss the application for fezolinetant (Veoza®) indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. A proposal has been received from the applicant and is under review. The output of negotiations will then be presented to the HSE Drugs Group for consideration.
The application remains under consideration with the HSE. The HSE cannot make any comment on possible outcomes from the ongoing process.
In line with the commitments set out in the Programme for Government, the Government will continue to prioritise improving the affordability of healthcare and medicines, including through ongoing review of community drugs schemes such as the Drugs Payment Scheme (DPS).
People who cannot, without undue hardship, arrange for the provision of medical services for themselves and their dependants may be eligible for a medical card under the General Medical Services (GMS) Scheme. In accordance with the Health Act 1970 (as amended), eligibility for a medical card is determined by the HSE.
The Drug Payment Scheme (DPS) provides for the refund of the amount by which expenditure on approved prescribed medicines or medical and surgical appliances exceeds a named threshold in any calendar month. The DPS is not means tested and is available to anyone ordinarily resident in Ireland. The DPS significantly reduces the cost burden for families and individuals with ongoing expenditure on medicines.
There has been a significant focus in recent years on improving access to, and the affordability of, healthcare services.
This includes reductions in the Drugs Payment Scheme threshold, reductions in the prescription charges per item and maximum monthly prescription charges under the DPS scheme, expansion of access to free GP care, and the abolition of all public in-patient hospital charges for children and adults. These measures continue to support affordable access to quality healthcare.
Any consideration of any future changes to the eligibility for medicines will be made in the context of current healthcare priorities and the budget available.